Securities code: Jiangxi Sanxin Medtec Co.Ltd(300453) securities abbreviation: Jiangxi Sanxin Medtec Co.Ltd(300453) Announcement No.: 2022018 Jiangxi Sanxin Medtec Co.Ltd(300453)
Announcement on investment in the construction of R & D and production base of hemodialysis series products
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without false records, misleading statements or major omissions.
Jiangxi Sanxin Medtec Co.Ltd(300453) (hereinafter referred to as “the company”) held the 17th meeting of the 4th board of directors and the 16th meeting of the 4th board of supervisors on March 15, 2022, deliberated and adopted the proposal on investing in the construction of R & D and production base of hemodialysis series products. The relevant matters are explained as follows:
1、 Investment overview
In order to further expand the market influence of the company’s hemodialysis series products and meet the market demand, the company urgently needs to improve the production capacity of hemodialysis series products. The company plans to use its own funds and bank loans of 568 million yuan to build a “R & D and production base project of hemodialysis series products”.
According to the Shenzhen Stock Exchange GEM Listing Rules and other laws and regulations, normative documents and the company’s foreign investment management system and other relevant provisions, this investment is within the approval authority of the company’s board of directors and does not need to be submitted to the general meeting of shareholders for deliberation.
This investment does not constitute a connected transaction, nor does it constitute a major asset reorganization stipulated in the administrative measures for major asset reorganization of listed companies.
2、 Basic information of the project
The R & D and production base project of hemodialysis series products is built in Jiangxi Nanchang Xiaolan economic development zone. The construction period of the project is from March 2022 to December 2024, with a construction period of 33 months. The project will purchase about 141 mu of land in Nanchang Xiaolan economic and Technological Development Zone, build production workshops, R & D test buildings, science and innovation buildings and production and living supporting facilities, and purchase corresponding production equipment. The implementation of this project will further enhance the image of the headquarters base of listed companies and build a national blood purification series product demonstration base.
1. Project Name: R & D and production base project of hemodialysis series products
2. Project location: Xiaolan Economic Development Zone, Nanchang County, Jiangxi Province
3. Source of project funds: self owned funds and bank loans
4. Project implementation subject: Jiangxi Sanxin Medtec Co.Ltd(300453)
5. Unified social credit Code: 913 Daqin Railway Co.Ltd(601006) 13026983x
6. Type: joint stock limited company (listed, natural person investment or holding)
7. Address: Xiaolan Economic Development Zone, Nanchang County, Jiangxi Province
8. Registered capital: three hundred ninety-four million twenty-seven thousand five hundred yuan only
9. Business scope: production and operation of medical devices; Medical equipment leasing; Production and sales of disinfectants (excluding hazardous chemicals); Operate the import business of raw and auxiliary materials, mechanical equipment, instruments and meters, spare parts and related technologies required by the production and scientific research of the enterprise and the incoming processing of the enterprise; Daily mask (non-medical) sales and daily mask (non-medical) production; Production and sales of labor protection articles; Production of sanitary products and disposable medical products, and sales of sanitary products and disposable medical products; Cosmetics production, wholesale and retail; Internet sales (excluding the sale of goods requiring license) and food Internet sales; Food production; Health food production and sales; Commodity sales, commodity wholesale and commodity production; China Trade Agency (for the above projects that need to be approved according to law, business activities can be carried out only after being approved by relevant departments)
10. Main financial data: as of December 31, 2021, the total assets of the company are 140 Xiangyang Changyuandonggu Industry Co.Ltd(603950) 0 yuan and the net assets are 978794700 yuan. In 2021, the company achieved a total operating income of 116428800 yuan and a net profit attributable to common shareholders of listed companies of 1559107 million yuan.
3、 Necessity and feasibility of project construction
The implementation of this project by the company can effectively drive the product and technology upgrading of the medical device industry, enhance the market competitiveness of domestic hemodialysis products, further accelerate the realization of import substitution, effectively reduce the economic pressure of Chinese dialysis patients and reduce the expenditure of national medical insurance fund. The continuous expansion of the market share of domestic hemodialysis series products will break the leading position of foreign manufacturers of similar products in the Chinese market and help to develop and expand national independent brands. Promote industrial technological progress, effectively promote technological exchanges between China and foreign countries, promote the upgrading of industrial products and the adjustment of product structure, and play a great role in industrial extension.
Since its establishment, the company has always focused on the R & D, manufacturing, sales and service of medical devices. In recent years, through continuous R & D and promotion in the field of hemodialysis, the company now has the ability to provide solutions for the whole industrial chain of blood purification. The company has rich experience in the production of hemodialysis series products and their corresponding production system, quality management system construction and continuous management, It is conducive to the smooth implementation of the R & D and production base project of the company’s hemodialysis series products.
To sum up, it is necessary and feasible for the company to implement the R & D and production base project of hemodialysis series products, whether considering the strategic direction and actual needs of the company’s development, or considering the experience and advantages accumulated by the company in the dialysis field, combined with the company’s capacity demand and the company’s superior production environment and conditions.
4、 Existing risks
1. The construction land of the investment project has not been obtained, and there are uncertainties in whether the land use right can be obtained, the final transaction price and the acquisition time. Therefore, there are still uncertainties in the construction of the project. The company will actively maintain close communication with relevant government departments and obtain land through public bidding procedures of government land bidding, auction and listing.
2. The capital of this investment project comes from its own funds and bank loans. The investment amount is large and the construction cycle is long. During the project construction, if the credit policy and the smoothness of financing channels change, the company may bear certain capital risks. In order to avoid and reduce the financial risks of project construction, the company will make full use of the advantages of listed companies to ensure capital operation and reduce construction costs. At the same time, the company will make an overall plan for capital arrangement in project construction, establish a scientific and reasonable supervision mechanism, and improve the utilization efficiency of funds, so as to ensure the good operation of project funds and ensure the smooth implementation of the project.
3. During the implementation of the project, there may still be risks such as project delay, implementation less than expected and income less than expected due to the influence of changing factors such as market environment, national and industrial policies, operation management, intensified market competition and product market sales, so that there is a certain difference between the final realized income of the project and the expected value. Therefore, the company will comprehensively strengthen operation and management, improve management efficiency, strengthen and implement effective internal control and risk prevention mechanism, actively pay attention to market environment, national and industrial policies, strengthen market research and judgment, and give full play to cost control advantages to prevent and reduce relevant risks.
4. The total investment, construction period and other data involved in this investment project are estimated. The specific situation shall prevail, and the estimated number may be adjusted. There is certain uncertainty whether the implementation of the project can achieve the expected purpose and effect, which does not represent the company’s prediction of future performance, nor does it constitute a performance commitment to investors, nor does it constitute a commitment to the amount of investment. The company will fulfill the obligation of information disclosure in time according to the follow-up progress of the project. Please invest rationally and pay attention to investment risks.
5、 Impact of the project investment on the company
Through the implementation of the R & D and production base project of hemodialysis series products, the company is conducive to further improve the production capacity of hemodialysis series products, effectively promote the realization of economies of scale of dialysis series products, improve the comprehensive benefits of hemodialysis series products and the competitive strength of the company, and lay a foundation for the future business expansion and long-term development of the company.
6、 Documents for future reference
1. Resolutions of the 17th meeting of the 4th board of directors;
2. Resolutions of the 16th meeting of the 4th board of supervisors;
3. Independent opinions of independent directors on matters related to the 17th meeting of the Fourth Board of directors.
It is hereby announced
Jiangxi Sanxin Medtec Co.Ltd(300453) board of directors March 17, 2022
